Venus Remedies has secured its first patent from Canada for its novel antibiotic adjuvant entity ‘Vancoplus’ and plans to launch the product there in the next two years.
The patent is valid up to May 2027. The company has already been marketing Vancoplus in India. Venus Remedies’ Baddi facility is already approved according to EU GMP standards for manufacturing the drug. Manu Chaudhary, Joint Managing Director, Director-Research, said, “The Canadian pharmaceutical market is the third fastest growing market globally.
With this patent, we hope to capture a significant share.” Vancoplus is growing at a CAGR of 50 per cent since the past three years. Apart from Canada, the patent for this product has already been granted in the US, South Africa, New Zealand and Ukraine and Australia.